CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Kura Oncology Inc - KURA CFD

    17.50
    0.74%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    Trading сonditions
    Spread 0.09
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026179 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026179%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003957 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003957%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Kura Oncology Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 17.63
    Open* 17.6
    1-Year Change* 60.58%
    Day's Range* 16.79 - 17.74
    52 wk Range 7.41-15.96
    Average Volume (10 days) 1.03M
    Average Volume (3 months) 20.50M
    Market Cap 1.08B
    P/E Ratio -100.00K
    Shares Outstanding 74.27M
    Revenue N/A
    EPS -2.02
    Dividend (Yield %) N/A
    Beta 0.84
    Next Earnings Date Feb 21, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Apr 19, 2024 17.50 0.21 1.21% 17.29 17.81 16.76
    Apr 18, 2024 17.63 -0.09 -0.51% 17.72 18.00 17.50
    Apr 17, 2024 17.96 -0.56 -3.02% 18.52 18.67 17.86
    Apr 16, 2024 18.55 -0.06 -0.32% 18.61 18.90 18.36
    Apr 15, 2024 18.96 -0.51 -2.62% 19.47 19.58 18.57
    Apr 12, 2024 19.42 -0.54 -2.71% 19.96 20.17 18.96
    Apr 11, 2024 20.36 0.18 0.89% 20.18 20.57 19.98
    Apr 10, 2024 19.85 -0.08 -0.40% 19.93 20.18 19.68
    Apr 9, 2024 20.65 0.36 1.77% 20.29 20.69 19.96
    Apr 8, 2024 20.39 0.20 0.99% 20.19 20.56 20.08
    Apr 5, 2024 20.33 0.36 1.80% 19.97 20.75 19.47
    Apr 4, 2024 20.30 -0.17 -0.83% 20.47 21.32 20.15
    Apr 3, 2024 20.30 0.04 0.20% 20.26 20.78 20.19
    Apr 2, 2024 20.47 -0.48 -2.29% 20.95 21.17 20.22
    Apr 1, 2024 21.79 0.68 3.22% 21.11 21.83 20.82
    Mar 28, 2024 21.29 0.37 1.77% 20.92 21.60 20.83
    Mar 27, 2024 21.12 0.76 3.73% 20.36 21.19 20.22
    Mar 26, 2024 20.35 -0.79 -3.74% 21.14 21.54 20.34
    Mar 25, 2024 20.94 -0.43 -2.01% 21.37 21.89 20.88
    Mar 22, 2024 21.35 -0.02 -0.09% 21.37 21.83 21.29

    Kura Oncology Inc Events

    Time (UTC) Country Event
    Wednesday, May 8, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q1 2024 Kura Oncology Inc Earnings Release
    Q1 2024 Kura Oncology Inc Earnings Release

    Forecast

    -

    Previous

    -
    Thursday, May 30, 2024

    Time (UTC)

    15:30

    Country

    US

    Event

    Kura Oncology Inc Annual Shareholders Meeting
    Kura Oncology Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    Thursday, August 1, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q2 2024 Kura Oncology Inc Earnings Release
    Q2 2024 Kura Oncology Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Total Operating Expense 139.865 131.458 91.899 67.479 63.381
    Selling/General/Admin. Expenses, Total 47.053 46.537 31.502 19.653 16.096
    Research & Development 92.812 84.721 60.397 47.826 46.787
    Operating Income -139.865 -131.458 -91.899 -67.479 -63.381
    Interest Income (Expense), Net Non-Operating 3.925 0.992 2.223 4.094 2.199
    Other, Net 0.1 0.051 0.245 0.735
    Net Income Before Taxes -135.84 -130.466 -89.625 -63.14 -60.447
    Net Income After Taxes -135.84 -130.466 -89.625 -63.14 -60.447
    Net Income Before Extra. Items -135.84 -130.466 -89.625 -63.14 -60.447
    Net Income -135.84 -130.466 -89.625 -63.14 -60.447
    Income Available to Common Excl. Extra. Items -135.84 -130.466 -89.625 -63.14 -60.447
    Income Available to Common Incl. Extra. Items -135.84 -130.466 -89.625 -63.14 -60.447
    Diluted Net Income -135.84 -130.466 -89.625 -63.14 -60.447
    Diluted Weighted Average Shares 66.99 66.352 53.077 41.946 35.191
    Diluted EPS Excluding Extraordinary Items -2.02777 -1.96627 -1.68858 -1.50527 -1.71768
    Diluted Normalized EPS -2.02777 -1.96326 -1.68858 -1.50527 -1.70353
    Unusual Expense (Income) 0.2 0.498
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 40.003 36.566 35.156 36.594 35.333
    Selling/General/Admin. Expenses, Total 11.821 11.374 12.488 11.621 11.075
    Research & Development 28.182 25.192 22.668 24.973 24.258
    Operating Income -40.003 -36.566 -35.156 -36.594 -35.333
    Interest Income (Expense), Net Non-Operating 2.829 2.497 2.042 1.09 0.564
    Other, Net
    Net Income Before Taxes -37.174 -34.069 -33.114 -35.504 -34.769
    Net Income After Taxes -37.174 -34.069 -33.114 -35.504 -34.769
    Net Income Before Extra. Items -37.174 -34.069 -33.114 -35.504 -34.769
    Net Income -37.174 -34.069 -33.114 -35.504 -34.769
    Income Available to Common Excl. Extra. Items -37.174 -34.069 -33.114 -35.504 -34.769
    Income Available to Common Incl. Extra. Items -37.174 -34.069 -33.114 -35.504 -34.769
    Diluted Net Income -37.174 -34.069 -33.114 -35.504 -34.769
    Diluted Weighted Average Shares 69.795 68.403 67.791 66.889 66.672
    Diluted EPS Excluding Extraordinary Items -0.53262 -0.49806 -0.48847 -0.53079 -0.52149
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.53262 -0.49806 -0.48847 -0.53079 -0.52149
    Unusual Expense (Income)
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 446.426 522.289 637.292 239.603 181.197
    Cash and Short Term Investments 437.985 517.96 633.32 236.891 178.985
    Cash & Equivalents 51.802 90.672 325.493 26.135 16.119
    Short Term Investments 386.183 427.288 307.827 210.756 162.866
    Total Receivables, Net 0.03 0.224
    Prepaid Expenses 8.441 4.329 3.972 2.682 1.988
    Total Assets 456.306 534.051 647.212 241.972 182.379
    Property/Plant/Equipment, Total - Net 6.382 8.246 8.355 0.278 0
    Property/Plant/Equipment, Total - Gross 7.985 9.09 8.641 0.136 0.092
    Accumulated Depreciation, Total -1.603 -0.844 -0.286 -0.092 -0.092
    Other Long Term Assets, Total 3.498 3.516 1.565 2.091 1.182
    Total Current Liabilities 24.057 22.455 26.024 15.564 13.615
    Accounts Payable 1.533 3.236 2.753 3.526 3.89
    Payable/Accrued 0.23
    Accrued Expenses 22.524 19.219 20.271 11.788 9.495
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 36.028 27.442 36.307 23.191 21.394
    Total Long Term Debt 9.158 0 4.25 7.25 7.5
    Long Term Debt 9.158 0 4.25 7.25 7.5
    Other Liabilities, Total 2.813 4.987 6.033 0.377 0.279
    Total Equity 420.278 506.609 610.905 218.781 160.985
    Preferred Stock - Non Redeemable, Net 0
    Common Stock 0.007 0.007 0.007 0.005 0.004
    Additional Paid-In Capital 997.111 941.359 913.354 431.322 310.849
    Retained Earnings (Accumulated Deficit) -568.808 -432.968 -302.502 -212.877 -149.737
    Other Equity, Total -8.032 -1.789 0.046 0.331 -0.131
    Total Liabilities & Shareholders’ Equity 456.306 534.051 647.212 241.972 182.379
    Total Common Shares Outstanding 68.314 66.572 66.194 45.384 38.148
    Current Port. of LT Debt/Capital Leases 0 3 0.25 0
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 459.917 485.646 416.45 446.426 436.391
    Cash and Short Term Investments 452.593 476.979 405.9 437.985 427.775
    Cash & Equivalents 28.74 49.124 27.059 51.802 90.937
    Short Term Investments 423.853 427.855 378.841 386.183 336.838
    Prepaid Expenses 7.324 8.667 10.55 8.441 8.616
    Total Assets 473.771 494.737 425.975 456.306 447.988
    Property/Plant/Equipment, Total - Net 9.338 5.186 5.761 6.382 7.018
    Property/Plant/Equipment, Total - Gross 11.576 7.208 7.57 7.985 8.415
    Accumulated Depreciation, Total -2.238 -2.022 -1.809 -1.603 -1.397
    Other Long Term Assets, Total 4.516 3.905 3.764 3.498 4.579
    Total Current Liabilities 27.525 23.899 19.233 24.057 24.745
    Accounts Payable 1.762 2.337 3.291 1.533 1.746
    Accrued Expenses 25.763 21.562 15.942 22.524 22.999
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases
    Total Liabilities 43.834 35.059 30.792 36.028 28.367
    Total Long Term Debt 9.289 9.244 9.2 9.158 0
    Long Term Debt 9.289 9.244 9.2 9.158
    Other Liabilities, Total 7.02 1.916 2.359 2.813 3.622
    Total Equity 429.937 459.678 395.183 420.278 419.621
    Common Stock 0.007 0.007 0.007 0.007 0.007
    Additional Paid-In Capital 1112.12 1104.94 1003.95 997.111 964.724
    Retained Earnings (Accumulated Deficit) -678.653 -640.051 -602.877 -568.808 -535.694
    Other Equity, Total -3.535 -5.222 -5.896 -8.032 -9.416
    Total Liabilities & Shareholders’ Equity 473.771 494.737 425.975 456.306 447.988
    Total Common Shares Outstanding 74.251 74.143 68.439 68.314 66.894
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Payable/Accrued
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -135.84 -130.466 -89.625 -63.14 -60.447
    Cash From Operating Activities -110.062 -104.551 -69.83 -54.76 -48.655
    Cash From Operating Activities 0.759 0.558 0.194 0 0.01
    Non-Cash Items 28.001 28.581 13.217 8.306 7.401
    Cash Interest Paid 0.073 0.784 0.419 0.43 0.641
    Changes in Working Capital -2.982 -3.224 6.384 0.074 4.381
    Cash From Investing Activities 32.627 -126.835 -99.936 -46.325 -79.3
    Other Investing Cash Flow Items, Total 33.253 -125.688 -97.765 -46.325 -79.3
    Cash From Financing Activities 38.565 -3.435 469.334 111.101 132.641
    Issuance (Retirement) of Stock, Net 29.14 4.426 469.584 111.101 133.264
    Issuance (Retirement) of Debt, Net 10 -7.25 -0.25 0 -0.623
    Net Change in Cash -38.87 -234.821 299.568 10.016 4.686
    Capital Expenditures -0.626 -1.147 -2.171
    Financing Cash Flow Items -0.575 -0.611
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -34.069 -135.84 -102.726 -67.222 -32.453
    Cash From Operating Activities -35.872 -110.062 -83.532 -62.522 -32.181
    Cash From Operating Activities 0.206 0.759 0.553 0.36 0.177
    Non-Cash Items 5.266 28.001 21.777 15.052 7.75
    Changes in Working Capital -7.275 -2.982 -3.136 -10.712 -7.655
    Cash From Investing Activities 11.129 32.627 79.945 8.135 -24.962
    Capital Expenditures -0.036 -0.626 -0.614 -0.233 -0.049
    Other Investing Cash Flow Items, Total 11.165 33.253 80.559 8.368 -24.913
    Cash From Financing Activities 0 38.565 3.852 2.972 0.303
    Issuance (Retirement) of Stock, Net 0 29.14 3.852 2.972 0.303
    Issuance (Retirement) of Debt, Net 10 0 0 0
    Net Change in Cash -24.743 -38.87 0.265 -51.415 -56.84
    Financing Cash Flow Items -0.575 0 0

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Kura Oncology Inc Company profile

    About Kura Oncology Inc

    Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company’s segment is engaged in discovery and development of medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and hematologic indications. It is developing KO-539, a small molecule inhibitor of the Lysine K-specific Methyltransferase 2A (KMT2A) interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Kura Oncology Inc revenues was not reported. Net loss increased 46% to $130.5M. Higher net loss reflects General and administrative - Balancing increase of 35% to $30.4M (expense), Stock-based Compensation in SGA increase of 82% to $16.1M (expense), Share-based compensation increase of 88% to $7.5M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.69 to -$1.97.

    Industry: Bio Therapeutic Drugs

    12730 High Bluff Drive, Suite 400
    SAN DIEGO
    CALIFORNIA 92130
    US

    Income Statement

    • Annual
    • Quarterly

    News

    Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

    Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

    07:56, 17 April 2024

    US Earnings Season : JP Morgan, Citigroup, Wells Fargo

    The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

    16:03, 11 April 2024

    Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

    The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

    09:22, 11 April 2024

    US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

    US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

    15:11, 9 April 2024

    How escalating geopolitical tensions are impacting oil markets

    The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

    13:34, 4 April 2024

    A way forward: a roundup of recent central bank decisions

    Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

    12:47, 22 March 2024

    Bank of Japan Preview: will the BOJ end negative interest rates?

    The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

    08:44, 18 March 2024

    People also watch

    BTC/USD

    63,755.20 Price
    -0.520% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 106.00

    ETH/USD

    3,056.23 Price
    -0.850% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 6.00

    US100

    17,037.80 Price
    -1.980% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 21:00 (UTC)
    Spread 7.0

    XRP/USD

    0.52 Price
    +2.820% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01168

    Still looking for a broker you can trust?

    Join the 610,000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading